Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Free Cash Flow (2022 - 2026)

Centessa Pharmaceuticals has reported Free Cash Flow over the past 4 years, most recently at -$55.8 million for Q4 2025.

  • Quarterly Free Cash Flow fell 30.42% to -$55.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$194.1 million through Dec 2025, down 36.58% year-over-year, with the annual reading at -$194.2 million for FY2025, 36.67% down from the prior year.
  • Free Cash Flow was -$55.8 million for Q4 2025 at Centessa Pharmaceuticals, up from -$58.5 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$21.4 million in Q3 2024 and troughed at -$60.1 million in Q2 2022.
  • The 4-year median for Free Cash Flow is -$43.4 million (2023), against an average of -$43.6 million.
  • The largest YoY upside for Free Cash Flow was 44.67% in 2025 against a maximum downside of 173.29% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$52.2 million in 2022, then soared by 40.48% to -$31.1 million in 2023, then plummeted by 37.72% to -$42.8 million in 2024, then plummeted by 30.42% to -$55.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Free Cash Flow are -$55.8 million (Q4 2025), -$58.5 million (Q3 2025), and -$22.5 million (Q2 2025).